Oncology · Pulmonology · 1 h ago
Editorial weighs primary-tumor surgery in stage IV EGFR-mutant lung cancer
An editorial discusses retrospective evidence that primary-tumor resection may improve outcomes in selected patients with stage IV EGFR-mutant NSCLC receiving tyrosine kinase inhibitors. The authors emphasize that selection bias, older TKI use and other limitations mean prospective trials are needed before surgery can be adopted routinely.
- Retrospective data associate resection with improved survival.
- Selection bias and treatment timing limit interpretation.
- Randomized trials are needed before routine adoption.
Systemic therapies have improved outcomes in stage IV non-small cell lung cancer (NSCLC), prompting renewed interest in local treatment. This editorial considers a retrospective study by Chang et al. comparing primary-tumor resection (PTR) plus tyrosine kinase inhibitor (TKI) treatment with TKI treatment alone in patients with stage IV EGFR-mutant lung adenocarcinoma. The study used propensity-score matching and included patients with good performance status (ECOG 0–1); the editorial does not report the cohort size or effect estimates.
The editorial says the study found significantly better progression-free and overall survival with PTR. Subgroups reported to benefit included patients aged 60 or older, never smokers, and those with T3–4, N0–2 or M1a disease. The authors propose that reducing tumor volume could delay the emergence of TKI-resistant clones, but describe this as a biologic rationale rather than established clinical benefit.
The evidence remains retrospective and susceptible to unmeasured selection bias. Surgery occurred a median of 4.7 months after TKI initiation, potentially excluding patients who progressed earlier; procedures varied, and most patients received first- or second-generation TKIs. The editorial notes that PTR is not standard practice and calls for randomized trials, including evaluation in the osimertinib era.
In practice
For patients with stage IV EGFR-mutant NSCLC whose disease is controlled on TKIs, retrospective findings suggest primary-tumor resection may be associated with longer progression-free and overall survival in selected groups. This does not establish that surgery should be added to routine care: the evidence is nonrandomized, may be affected by patient selection and survival-to-surgery bias, and largely reflects earlier-generation TKIs. The editorial states that PTR is not standard practice and that randomized trials, including in the osimertinib era, are needed.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Annals of Surgical Oncology: Editorial Comment: Rethinking Local Control in Stage IV EGFR-Mutant NSCLC: A Biologic Rationale for Primary Tumor Resection in the Era of Targeted Therapy ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.